Felipe Couñago: URONCOR 06-24 Trial Data
Felipe Couñago, National Clinical Director of GenesisCare Spain, shared a post on X:
“New online!
URONCOR 06-24
Phase III on optimal ADT + salvage RT duration after prostatectomy in Prostate Cancer.
Thanks to co-authors, patients, families and team! Free 50 days.”
Title: Duration of androgen deprivation therapy with salvage radiotherapy in patients with prostate cancer and biochemical recurrence after surgery: Initial recruitment data in the phase III URONCOR 06-24 trial
Authors: C. González San Segundo, F. López-Campos, A. Gómez Iturriaga, M. Santos, A. Ocanto, L. Montezuma, A.M. Boladeras-Inglada, L. Glaria, S. Guardado, A. Rodríguez, I. Henríquez, J. Olivera, V. Duque-Santana, J. Garre, S. Moreno, J. Valero, A.J. Conde, A. Doval, G. Sancho, P. Martin Nieto, F. Couñago
Read the Full Article.
More posts featuring Felipe Couñago.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023